Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity

Journal of Clinical Oncology

Volumn 13, Issue 7, 1995, Pages 1663-1670

  Etienne, M C ^a   Cheradame S ^a   Fischel, J L ^a   Formento, P ^a   Dassonville, O ^a   Renee N ^a   Schneider, M ^a   Thyss, A ^a   Demard, F ^a   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR LOCALIZATION;

EID: 0028982820     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.7.1663     Document Type: Article

References (47)

1. Vokes EE, Schilsky RL, Weichselbaum RR, et al: Induction chemotherapy with cisplatin, fluorouracil and high-dose leucovorin for locally advanced head and neck cancer: A clinical and pharmacological analysis. J Clin Oncol 8:214-247, 1990
2. Swain SM, Lippman ME, Egan EG, et al: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:890-899, 1989
3. Peters GJ, Van Groeningen CJ: Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2:469-480, 1991
4. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
5. Dreyfuss AI, Clark JR, Wright JR, et al: Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 112:167-172, 1990
6. Amrein PC, Weitzman SA: Treatment of squamous cell carcinoma of the head and neck with cisplatin and 5 fluorouracil. J Clin Oncol 3:1632-1639, 1985
7. Kish J, Drelichman A, Jacobs J, et al: Clinical trial of cisplatin and 5FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 66:471-476, 1982
8. Thyss A, Schneider M, Santini J, et al: Induction chemotherapy with cis platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer 54:755-760, 1986
9. Parker WB, Cheng YC: Metabolism and mechanism of action of 5-fluorouracil. Pharm Ther 48:381-395, 1990
10. Grem JL: Fluorinated pyrimidine, in Chabner BA, Collins JM (eds): Cancer Chemotherapy, Principles and Practice. Philadelphia, PA, Lippincott 1990, pp 180-225
11. Reichard, Sköld O, Klein G, Revesz L, et al: Studies on resistance against 5-fluorouracil. Enzymes of the uracil pathway during development of resistance. Cancer Res 22:235-243, 1962
12. Ardalan B, Cooney DA, Jayaram HN, et al: Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res 40:1431-1437, 1980
13. Houghton JA, Maroda SJ, Phillips JO, et al: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in mice. Cancer Res 41:144-149, 1981
14. Mulkins MA, Heidelberg C: Biochemical characterisation of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 42:965-972, 1982
15. Clark JL, Berger SH, Mittelman A, et al: Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 71:261-265, 1987
16. Lenz HJ, Leichman CG, Danenberg P, et al: Thymidylate synthase gene expression predicts response of primary gastric cancer to 5-fluorouracil-leucovorin-cisplatin. Proc Am Soc Clin Oncol 199:585, 1993 (abstr)
17. Johnston PG, Lenz HJ, Danenberg KD, et al: Thymidylate synthase protein and gene expression predicts for response to 5fluorouracil-leucovorin chemotherapy in patients with colorectal and gastric cancer. Proc Am Soc Clin Oncol 196:569, 1994 (abstr)
18. Leichman CG, Lenz HJ, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer resistance to protracted infusion 5-fluorouracil and weekly leucovorin. Proc Am Soc Clin Oncol 201:592, 1994 (abstr)
19. Ardalan B, Reddy KR, Livingstone A, et al: Thymidylate synthase gene expression in normal and malignant gastrointestinal tissues in relation to in vivo response to 5FU based therapy. Proc Am Assoc Cancer Res 549:3271, 1994 (abstr)
20. Horikoshi T, Danenberg KD, Stadlbauer THW, et al: Quantification of thymidylate synthase, dihydrofolate reductase and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52:108-116, 1992
21. Peters GJ, Laurensse E, Leyva A, et al: Sensitivity of human, murine and rat cells to 5-fluorouracil and 5′-deoxy-5fluorouridine in relation to drug metabolizing enzymes. Cancer Res 46:20-28, 1986
22. Aschele C, Sobrero A, Faderan MA, et al: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855-1864, 1992
23. Naguib FNM, El Kouni AM, Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405-5412, 1985
24. Beck A, Etienne MC, Chéradame S, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30:1517-1522, 1994
25. Moran RG, Spears CP, Heidelberger C: Biochemical determinants of tumor sensitivity to 5-fluoro-2′deoxyuridilate, 2′deoxyuridine and thymidylate synthase. Proc Natl Acad Sci USA 76:1456-1460, 1979
26. Harris BE, Song R, Soong S, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201, 1990
27. Sommadossi JP, Gewirtz DA, Diasio RB, et al: Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high-performance liquid chromatography. J Biol Chem 257:8171-8176, 1982
28. Spears CP, Gustavsson BG: Methods for thymidylate synthase pharmacodynamics: Serial biopsy, free and total TS, FdUMP and dUMP, and H4 Pteglu and CH2-H4 Pteglu assays, in Rustum Y, McGuire JJ (eds): The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. New York, NY, Plenum, 1988, pp 97-104
29. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
30. Dimery IW, Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 86:95-111, 1993
31. Etienne MC, Bernard S, Fischel JL, et al: Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer 63:372-377, 1991
32. Scanlon KJ, Newman EM, Lu Y, et al: Biochemical basis for cisplatin and 5-fluorouracil synergisin in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923-8925, 1986
33. Shirasaka T, Shimamoto Y, Cheshimo H, et al: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32:167-172, 1993
34. De Braud F, Bajetta E, Colleoni M, et al: Fluorouracil and folinic acid in advanced colorectal cancer resistant to fluoropyrimidines, a study by the Italian Trials in Medical Oncology group. Ann Oncol 3:132, 1992 (suppl 5) (abstr)
35. Johnston PG, Drake JC, Trepel J, et al: Immunological quantification of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil sensitive and resistant human cancer cell lines. Cancer Res 52:4306-4312, 1992
36. Van der Wilt CL, Pinedo HM, Smid K, et al: Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 52:2922-2928, 1992
37. Johnston PG, Fischer E, Rockette HE, et al: Thymidylate synthase expression is an independent predictor of survival/disease free survival in patients with rectal cancer. Proc Am Soc Clin Oncol 202:599, 1993 (abstr)
38. Peters GJ, Van Groeningen CJ, Van der Wilt C, et al: Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin Oncol 19:26-35, 1992
39. Maehara Y, Nagayama S, Okazaki H, et al: Metabolism of 5-fluorouracil in various human normal and tumor tissues. Gann 72:824-827, 1981
40. Ho DH, Townsend L, Luna MA, et al: Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6:781-784, 1986
41. Harris BE, Song R, He YJ, et al: Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol 37:4759-4762, 1988
42. 19F nuclear magnetic resonance spectroscopy. Cancer Res 54:4321-4326, 1994
43. Yee LK, Allegra CS, Steinberg SM, et al: Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin and interferon α-2a. J Natl Cancer Inst 84:1820-1825, 1992
44. Milano G, Fischel JL, Etienne MC, et al: Inhibition of dihydropyrimidine dehydrogenase by α-interferon: Experimental data on human tumor cell lines. Cancer Chemother Pharmacol 34:147-152, 1994
45. Daher GC, Naguib FNM, El Kouni MH, et al: Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. Biochem Pharmacol 41:1887-1893, 1991
46. Naguib FNM, Hao SN: Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5 benzyloxybenzyluracil. Proc Am Assoc Cancer Res 34:438, 1993
47. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994